NASDAQ:TRDA Entrada Therapeutics Q1 2026 Earnings Report $6.46 +0.15 (+2.38%) Closing price 04:00 PM EasternExtended Trading$6.45 -0.01 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Entrada Therapeutics EPS ResultsActual EPS-$0.95Consensus EPS -$1.06Beat/MissBeat by +$0.11One Year Ago EPSN/AEntrada Therapeutics Revenue ResultsActual Revenue$0.88 millionExpected Revenue$2.92 millionBeat/MissMissed by -$2.04 millionYoY Revenue GrowthN/AEntrada Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time7:00AM ETUpcoming EarningsEntrada Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Entrada Therapeutics Earnings HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)June 9 at 9:31 AM | theglobeandmail.comEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.June 12 at 1:00 AM | InvestPub (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 4, 2026 | prnewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyJune 2, 2026 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 2, 2026 | globenewswire.comSee More Entrada Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email. Email Address About Entrada TherapeuticsEntrada Therapeutics (NASDAQ:TRDA) (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.View Entrada Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Why Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for Shareholders Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
